Lupin informs about press release

24 Dec 2018 Evaluate

Lupin has informed about submission of a Press Release as regards AbbVie Inc. having licensed the company’s MALTI (Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein I) inhibitor program through which AbbVie gains exclusive global rights to develop and commercialize the company’s MALTI inhibitors. This disclosure is under pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2137.15 -27.90 (-1.29%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×